SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
NORTHBROOK, Ill., Feb. 11, 2016 -- Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced today that it will report its results for the fourth quarter ended December 30, 2015 after the market close on Wednesday, February 24, 2016. The company will also hold a live investor conference call and webcast at 5pm Eastern Time.
Conference Call & Webcast
Wednesday, February 24 @ 5pm Eastern Time
| Domestic: | 888-438-5453 |
| International: | 719-325-2144 |
| Passcode: | 8370643 |
| Webcast: | http://www.nanosphere.us/investors |
| Replays – Available through March 9, 2016 | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Passcode: | 8370643 |
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
Contacts Investors: Michael Rice, LifeSci Advisors 646-597-6979 [email protected] Media: Zachary Crowther, Director of Marketing 847-400-9074 [email protected]
